医药行业周报：创新药对外授权节奏有望恢复-20251019

Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry [1] Core Insights - The rhythm of licensing-out for innovative drugs is expected to recover, with China's innovative advantages continuing to be maintained. As of August 2025, China has reached 93 licensing-out transactions, accounting for 32% of global transactions, with a total upfront payment of $4.3 billion and a total amount of $84.8 billion, both exceeding last year's totals and likely to set a new high in nearly a decade [2] - The ESMO conference is highlighted for the release of key Phase III clinical data, which will significantly impact future treatment trends. Notable results from Chinese innovative drugs are expected to be presented [3] - Breakthroughs in small nucleic acid drugs for chronic diseases such as hypertension and dyslipidemia are noted, with significant partnerships and potential milestone payments indicating a broad commercial outlook [4] - The trend towards oral autoimmune drugs is gaining attention, with major pharmaceutical companies showing interest in oral peptide drugs, indicating a shift in treatment approaches for autoimmune diseases [5] Summary by Sections 1. Pharmaceutical Market Tracking - The pharmaceutical industry has underperformed compared to the CSI 300 index, with a recent weekly decline of 3.65% and a monthly decline of 6.10%, ranking 21st and 24th respectively among 31 industry indices [21][22] 2. Pharmaceutical Sector Trends and Valuation - The pharmaceutical sector's recent performance shows a 6.10% decline over the past month, underperforming the CSI 300 index by 5.29 percentage points. The sector's current PE ratio is 38.08, above the historical average of 31.32 [41][45] 3. Recent Research Achievements - The report outlines various recent research achievements by the team, including deep reports on the growth of the blood products industry and the potential of GLP-1 drugs in chronic disease management [50] 4. Important Industry Policies and News - Recent policies include the National Healthcare Security Administration's push for instant settlement reforms and pilot programs for traditional Chinese medicine payment models, indicating a shift towards more efficient healthcare financing [53][54]